Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

General Updates | iwGPRC5D 2025: highlights from the workshop

Saad Usmani and Sham Mailankody • 22 Mar 2025
General Updates
Multiple Myeloma

In this video, Saad Usmani, MD, MBA, FACP, and Sham Mailankody, MBBS, Memorial Sloan Kettering Cancer Center, New York City, NY, share their highlights from the 1st International Workshop on GPRC5D-Targeted Myeloma Therapies (iwGPRC5D), emphasizing the excitement and progress made in understanding GPRC5D as a target, its role in multiple myeloma, and the challenges of managing toxicities associated with these therapies.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Saad Usmani

The value of iwHRMM and wrap-up of the 2025 meeting 2:23
The value of iwHRMM and wrap-up of the 2025 meeting
Saad Usmani • 24 Oct 2025
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Mohamad Mohty et al. • 15 Jul 2022
Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies
Ajai Chari et al. • 4 Nov 2024
Factors to consider when selecting patients with multiple myeloma for treatment with bispecifics 0:42
Factors to consider when selecting patients with multiple myeloma for treatment with bispecifics
Saad Usmani • 9 Sep 2024

More from Sham Mailankody

Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
Innovative approaches to trial design in high-risk myeloma & how these may improve data collection 3:13
Innovative approaches to trial design in high-risk myeloma & how these may improve data collection
Sham Mailankody • 24 Oct 2025
Practical considerations for T-cell engagers in multiple myeloma: recent data, sequencing, & more 19:40
Practical considerations for T-cell engagers in multiple myeloma: recent data, sequencing, & more
Doris Hansen et al. • 12 Apr 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals